Early-stage Development of the CoRISMA Mechanical Circulatory Support (CMCS) System for Heart Failure Therapy
- PMID: 39037566
- DOI: 10.1007/s13239-024-00743-0
Early-stage Development of the CoRISMA Mechanical Circulatory Support (CMCS) System for Heart Failure Therapy
Abstract
Purpose: CoRISMA MCS Systems Inc (Hamden CT) is developing an innovative mechanical circulatory support system (CMCS) as a durable therapeutic option for heart failure (HF) patients. The CMCS system is comprised of an axial flow pump, non-contacting hydrodynamic bearings, and integrated DC motor designed to be fully implantable in a left atrial (LA) to aortic (Ao) configuration; this unloading strategy may be particularly beneficial for HF patients with preserved ejection fraction (HFpEF). The small (5.5 cm3), lightweight (20 g), and low power (5-7 W) device design should allow for a less invasive off-pump implant. We present early-stage engineering development and testing of the prototype CoRISMA pumps.
Methods: Computational fluid dynamics (CFD) modeling was performed to evaluate flow and shear in two impeller (3 blades, 0.5 mm thickness, 8.9 mm diameter, 0.15 mm gap, polished titanium) and diffusor (5 blades, polished titanium) candidate designs. Test apparatuses were custom built to expedite development of the impeller/diffuser designs and iteratively refine the CFD models. Two candidate impeller/diffusor designs were fabricated and tested in each of the two test apparatuses (n = 4 impeller/diffuser + test fixture configurations) in static mock flow loops (hydrodynamic H-Q curves, 3.5 cP glycerol solution at 37 °C), and in dynamic mock flow loops (hemodynamics, 3.5 cP glycerol solution at 37 °C) tuned to HF conditions (mean aortic pressure 50 mmHg, central venous pressure 15 mmHg, aortic flow 3.0 L/min, and heart rate 80 bpm).
Results: CFD predicted flows of 4.56 L/min and 4.82 L/min at 100 mmHg for impellers/diffusers 1 and 2, respectively. Impeller 2 required less torque to generate a 6% increase in fluidic flow, and the diffuser had a larger area of high pressure, indicative of lower friction, which likely contributed to the increased efficiency. Experimental testing for all four configurations in the static and dynamic mock loops met performance metrics as evidenced by generating 4.0-4.5 L/min flow against 70-76 mmHg pressure at 25,000 rpm and restoring hemodynamics in the dynamic mock flow loop (MAP = 80 mmHg, CVP = 0 mmHg, total flow = 5.5 L/min) from baseline simulated HF test conditions.
Conclusion: These results demonstrate proof-of-concept of the early engineering design and performance of the prototype CoRISMA pumps. Engineering specifications, challenges observed, and proposed solutions for the next design iteration were identified for the continued development of an effective, reliable, and safe LA-to-Ao CMCS system for HF patients. Current design plans are underway for incorporating a wireless energy transfer system for communication and power, eliminating the need for and complications associated with an external driveline, to achieve a fully-implantable system.
Keywords: Computational fluid dynamics; Heart failure; Impeller; Mechanical circulatory support; Mock circulatory loop.
© 2024. The Author(s) under exclusive licence to Biomedical Engineering Society.
Conflict of interest statement
Declarations. Competing Interests: James Kelley, Daniel Tamez, Daisy Cross, Mark Kelley, Varun Yetukuri, Michael Theran, Jessica Illg are employees of CoRISMA MCS Systems Inc. Daniel Tamez is a former employee of Artio Medical Inc. Gretel Monreal, Steven Koenig, and Mark Slaughter are investigators on a subcontract with CoRISMA MCS Systems Inc. Gretel Monreal, Steven Koenig, Daniel Tamez and Mark Slaughter are investigators on a NIH grant (R44HL144214) with Inspired Therapeutics unrelated to this project. Gretel Monreal, Steven Koenig, and Mark Slaughter were investigators on now-completed NIH grants all unrelated to this project: R43HL152767 (Bionet Sonar), R43HL149451 (Bionet Sonar), R43HL142385 (MAST), R43HL152894 (MAST), R43HL142337 (Cor Habere), R43HL152774 (RT Cardiac Systems), R43HLI44214 (Inspired Therapeutics). Gretel Monreal and Steven Koenig were investigators on a now-completed NSF EPSCoR grant unrelated to this project. Gretel Monreal and Steven Koenig are investigators on a Kentucky Academy of Science Athey Science Education and Outreach Grant unrelated to this project. Steven Koenig is an investigator on a NIH grant (R01HL150346) unrelated to this project. Steven Koenig was an investigator on a now-completed NIH grant (R43NS115226, Bionet Sonar), unrelated to this project. James Kelley is a principle at EVO3 Medical. Mark Slaughter is a consultant with CoRISMA MCS Systems Inc and Magenta Medical and is on the advisory board of Medtronic. Mark Slaughter is the Editor-in-Chief of ASAIO Journal. Gretel Monreal is supported in part by a gift from Robert M. Prizant to the Legacy Foundation of Kentuckiana. Citation Diversity Statement: The authors support diversity and agree that increasing diversity awareness is important. The authors decline to provide a citation diversity statement, as we are unable/unwilling to attempt to classify people by gender, race, ethnicity, or other features based on their name.
References
-
- Kapelios CJ, Shahim B, Lund LH, Savarese G. Epidemiology, clinical characteristics and cause-specific outcomes in heart failure with preserved ejection fraction. Card Fail Rev. 2023;9:e14. https://doi.org/10.15420/cfr.2023.03 - DOI - PubMed - PMC
-
- Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Cheng S, Delling FN, Elkind MSV, Evenson KR, Ferguson JF, Gupta DK, Khan SS, Kissela BM, Knutson KL, Lee CD, Lewis TT, Liu J, Loop MS, Lutsey PL, Ma J, Mackey J, Martin SS, Matchar DB, Mussolino ME, Navaneethan SD, Perak AM, Roth GA, Samad Z, Satou GM, Schroeder EB, Shah SH, Shay CM, Stokes A, VanWagner LB, Wang NY, Tsao CW; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2021 Update: A report from the American Heart Association. Circulation. 2021;143:e254-e743. https://doi.org/10.1161/CIR.0000000000000950 - DOI - PubMed
-
- Griffin WP, Savage EB, Clark RE, Pacella JJ, Johnson GA, Magovern JA, Magovern GJ Sr. AB-180 circulatory support system: summary of development and phase I clinical trial. ASAIO J. 1998 Sep-Oct;44(5):M719-24. https://doi.org/10.1097/00002480-199809000-00085
-
- Goldstein AH, Monreal G, Kambara A, Spiwak AJ, Schlossberg ML, Abrishamchian AR, Gerhardt MA. Partial support with a centrifugal left ventricular assist device reduces myocardial oxygen consumption in chronic, ischemic heart failure. J Card Fail. 2005;11:142–51. https://doi.org/10.1016/j.cardfail.2004.07.005 - DOI - PubMed
-
- Monreal G, Gerhardt MA. Left ventricular assist device support induces acute changes in myocardial electrolytes in heart failure. ASAIO J. 2007;53:152–8. https://doi.org/10.1097/MAT.0b013e3180302a8b - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
